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Abstract The Gq-coupled agonists phenylephrine and endothe-
lin-1 each activate protein synthesis in cardiomyocytes as part
of the programme that leads to cardiac hypertrophy. Here we
show that they each induce the dephosphorylation of elongation
factor (eEF) 2, a protein that in its dephosphorylated state
mediates the translocation step of elongation. The ability of
both agonists to induce dephosphorylation of eEF2 requires sig-
nalling via the mTOR and MEK/Erk signalling pathways, but is
independent of phosphoinositide 3-kinase. Expression of an ac-
tivated form of MEK leads to dephosphorylation of eEF2, in an
mTOR independent manner, indicating that signalling via
MEK/Erk su⁄ces to cause dephosphorylation of eEF2.
- 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Eukaryotic elongation factor 2 (eEF2) mediates the trans-
location step of peptide-chain elongation in the cytoplasm of
mammalian cells. This step involves the co-ordinated move-
ment of the ribosome relative to the mRNA by three nucleo-
tides and occurs every time a new amino acid has been added
to the nascent polypeptide chain. eEF2 is a phosphoprotein
[1,2] : phosphorylation at threonine 56 prevents eEF2 from
binding to ribosomes and thus inhibits its activity [3^5]. The
kinase that phosphorylates eEF2 is an unusual and highly
speci¢c one. It belongs to a small group of protein kinases
whose primary sequences are unrelated to main serine/threo-
nine/tyrosine kinase superfamily [6,7]. Its only known sub-
strate is eEF2 and it is therefore known as eEF2 kinase.
This is a calcium/calmodulin (CaM)-dependent enzyme [2,8]
and was formerly called Ca/CaM-kinase III [1,2].
Insulin brings about the dephosphorylation of eEF2 in sev-
eral cell types [9^12] and this e¡ect can be blocked by rapa-
mycin, a compound that inhibits the function of the mamma-
lian target of rapamycin, mTOR. Recent work has shown that
p70 S6 kinase 1 (S6K1), a target of the mTOR pathway,
phosphorylates eEF2 kinase (at Ser365, rat), resulting in de-
creased activity of eEF2 kinase [11]. S6K1 is activated by
insulin in a rapamycin-sensitive manner (for review see [13]).
It thus provides a link between insulin, mTOR signalling and
the inactivation of eEF2 kinase leading to the stimulation of
eEF2 and of peptide-chain elongation.
Ser365 in eEF2 kinase is also phosphorylated by 90-kDa
ribosomal protein S6 kinase (p90RSK), a protein kinase that
lies downstream of the classical Erk (MAP kinase) pathway
[11]. This could allow stimuli that activate Erk signalling to
turn on peptide-chain elongation. However, very little work
has been carried out to establish whether MEK/Erk signalling
does regulate eEF2 phosphorylation in response to physiolog-
ical agonists and it is also unclear whether MEK/Erk/p90RSK
is su⁄cient to cause dephosphorylation of eEF2 in response to
such stimuli. Here we have studied the e¡ects of Gq-protein
coupled receptor agonists (phenylephrine, PE, and endothelin-
1, ET-1) on the phosphorylation of eEF2 in adult rat cardio-
myocytes. These agonists are of particular interest because
they stimulate protein synthesis and induce hypertrophy of
ventricular cardiomyocytes (see [14,15]). This clinically impor-
tant condition is primarily characterised by inappropriate
stimulation of protein accumulation, leading to increased
cell size which underlies cardiac hypertrophy. Another agent
that causes cardiac hypertrophy, angiotensin II, has been re-
ported to induce dephosphorylation of eEF2 through mecha-
nisms that require signalling via MEK and phosphoinositide
(PI) 3-kinase [16]. However, PE and ET-1 stimulate cardiac
protein synthesis without activating signalling through PI 3-
kinase [17], although they do activate the MEK/Erk pathway
[18]. Increasing evidence points to a key role for MEK/Erk
signalling in the induction of hypertrophy by PE and ET-1
[19^21]. Two key questions that we have addressed here is
whether PE and ET-1 regulate eEF2 phosphorylation via
MEK-dependent mechanisms and, if so, whether activation
of this pathway is su⁄cient for dephosphorylation of eEF2.
2. Materials and methods
2.1. Chemicals, biochemicals and other reagents
These were obtained as described earlier [18] with the following
additions. The anti-phospho (Thr56)eEF2 and anti-eEF2 antibodies
were described earlier [22,23]. Antisera for S6K1 and p90RSK were
kindly provided by the Division of Signal Transduction Therapy,
University of Dundee. Wortmannin was from Calbiochem (Notting-
ham, UK).
0014-5793 / 02 / $22.00 G 2002 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 2 ) 0 3 5 3 6 - 6
*Corresponding author. Fax: (44)-1382-322 424.
E-mail address: c.g.proud@dundee.ac.uk (C.G. Proud).
1 Present address: Division of Cell Biology and Immunology, Faculty
of Life Sciences, University of Dundee, Dundee, DD1 5EH, UK.
Abbreviations: ARVC, adult rat ventricular cardiomyocyte; eEF2,
eukaryotic elongation factor 2; Erk, extracellular ligand-regulated ki-
nase; ET-1, endothelin-1; MEK, mitogen-activated protein-ERK ki-
nase; p90RSK, 90-kDa ribosomal protein S6 kinase; PE, phenyleph-
rine; S6K1, ribosomal protein S6 kinase 1
FEBS 26686 23-10-02
FEBS 26686 FEBS Letters 531 (2002) 285^289
2.2. Isolation, virus infection, culture, treatment and extraction of
cardiac myocytes
Ventricular myocytes were isolated by collagenase digestion from
adult rat hearts as described previously [10]. Cells were plated in
dishes pretreated with laminin and cultured overnight in 199 medium
[10]. Virus infection using adenovirus encoding an activated form of
MEK (MEKCA ; from Dr S. Tanaka, Tokyo, Japan [24], in which key
regulatory serine residues in the catalytic domain of MEK are mu-
tated to glutamates) was performed as described earlier [18]. The
control adenovirus expressing L-galactosidase was kindly provided
by Professor T. Kuroki (Tokyo, Japan [25]). Following virus infec-
tion, cells were given fresh medium and incubated for a further 36 h
before treatment. Cells were lysed (50 mM Tris, pH 7.5, 1 mM
EGTA, 1 mM EDTA, 1 mM Na3VO3, 50 mM NaF, 5 mM sodium
pyrophosphate, 270 mM sucrose, 1% (v/v) Triton X-100, 1 mM DTT,
1 WM microcystin, 1 Wg/ml leupeptin, 1 Wg/ml pepstatin, 1 Wg/ml
antipain, and 0.2 mM phenylmethylsulphonyl £uoride) and extracts
were prepared as described earlier [10]. Protein concentrations were
determined by the method of Bradford [26].
2.3. Gel electrophoresis and western blotting
These procedures were performed as described earlier [18,27] using
Immobilon0 membrane. Blots were developed by enhanced chemilu-
minescence (ECL).
2.4. Other procedures
S6K1 was assayed after immunoprecipitation using a 32-residue
peptide substrate as described earlier [28]. p90RSK activity was assayed
after immunoprecipitating the enzyme from 150 Wg of adult rat ven-
tricular cardiomyocyte (ARVC) cell lysates with anti-p90RSK antibody
(from DSTT, Dundee). Immunoprecipitates were washed once with
cell lysis bu¡er containing 0.5M NaCl, once with cell lysis bu¡er, once
with kinase bu¡er (50 mM MOPS, pH7.5, 0.1 mM EDTA, 0.03%
(w/v) Brij 35, 0.1% (v/v) L-mercaptoethanol), and were assayed in
this kinase bu¡er containing 5 WM PKI, 10 mM MgCl2/100 WM
ATP and 2 WCi [Q-32P]ATP at 30‡C for 20 min, using Crosstide (GRP-
RTSSFAEG, 50 WM, from Dr. D.R. Alessi, Dundee) as substrate.
3. Results and discussion
3.1. PE and ET-1 elicit the dephosphorylation of eEF2 in
ARVC
As shown in Fig. 1, treatment of ARVC with either PE or
ET-1 resulted in the dephosphorylation of eEF2 as deter-
mined using a phosphospeci¢c antibody that only detects
eEF2 when it is phosphorylated at Thr56 [22]. Separate im-
munoblots with an antibody that detects eEF2 irrespective of
its state of phosphorylation demonstrated equal loading of all
lanes. In each case, dephosphorylation was already evident
after 5 min of treatment and further dephosphorylation was
seen up to 30^60 min following addition of agonist, after
which phosphorylation increased. In the case of ET-1 treat-
ment, phosphorylation had returned to initial levels by 120
min. In the case of PE, phosphorylation was higher at 120
min than at 30/60 but was still below the control levels seen at
time zero.
Given that the e¡ects of PE were greater than those of
ET-1, most subsequent work focused on the e¡ects of PE.
To assess the signalling pathways that might mediate the ef-
fects of this agent on eEF2 phosphorylation, we studied the
activities of S6K1 and p90RSK in cells treated with PE. Both
enzymes can phosphorylate and inactivate eEF2 kinase, at
least in vitro [11], and are therefore candidates for mediating
the e¡ect of PE on the phosphorylation of eEF2.
3.2. PE activates p90RSK and S6K1 with distinct kinetics
As shown in Fig. 2A, PE elicited a rapid and marked acti-
vation of p90RSK. Activity peaked by 5 min and then fell
gradually, although it was still sustained well above basal
levels by 120 min. In contrast, activation of S6K1 was slower
(reaching a maximum only after 60 min; Fig. 2B), as reported
earlier by us for the activation of this enzyme [17] and of
S6K2 [18] by PE in these cells. As shown in Fig. 1A, eEF2
phosphorylation had already decreased by 5 min, a time at
which there is no signi¢cant activation of S6K1 (or S6K2
[18]). It is therefore most unlikely that phosphorylation of
eEF2 kinase by S6K1/2 is responsible for this early fall in
eEF2 phosphorylation. Activation of S6K1 by ET-1 in
ARVC also occurs after a similar lag period to that seen in
response to PE, but reaches a peak earlier at around 30 min
[17]. This may, at least in part, explain the di¡erent kinetics
observed here for the e¡ects of ET-1 and PE on the phos-
phorylation of eEF2.
3.3. Dephosphorylation of eEF2 is blocked by inhibitors of
MEK or mTOR
To study the upstream signalling pathways that mediate the
dephosphorylation of eEF2 in response to PE or ET-1, we
selected a time point at which dephosphorylation was maxi-
mal. This was 1 h for PE and 30 min for ET-1. Fig. 3A,B
shows that the dephosphorylation of eEF2 induced by PE
or ET-1 was blocked by treatment of cells with either rapa-
mycin or PD098059, indicating that signalling via both
mTOR and MEK is required for this e¡ect. The dephosphor-
ylation of eEF2 in response to PE or ET-1 was also blocked
by two other structurally unrelated inhibitors of MEK, U0126
[29] and PD184352 [30] (data not shown), strongly supporting
the idea that signalling through MEK is essential for this
e¡ect. These observations are not consistent with an ability
of p90RSK alone to bring about the dephosphorylation of
eEF2, via phosphorylation and inactivation of eEF2 kinase
[11]. If this were the case, one would not expect rapamycin
to block the e¡ect (as it does not impair activation of the Erk
pathway). In fact, we have shown earlier that MEK signalling
is required for activation of S6K1 [17] or S6K2 [18] by PE or
ET-1. This likely explains why the MEK inhibitors block the
dephosphorylation of eEF2, since they will prevent the acti-
vation of both p90RSK and the S6 kinases by PE/ET-1.
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Fig. 1. PE and ET-1 induce dephosphorylation of eEF2 in adult
cardiomyocytes. A,B: ARVC were treated with PE (10 WM) or
ET-1 (0.1 WM) for the times indicated and cells were then lysed and
equal amounts of cell extract protein were analysed by SDS^PAGE
and Western blotting, using antisera that recognise eEF2 only when
it is phosphorylated at Thr56 (upper part of each panel, indicated
P-eEF2) or eEF2, irrespective of its state of phosphorylation (lower
part of each panel, eEF2). ‘0’ indicates untreated cells. All experi-
ments were performed at least three times with similar results.
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It remained possible that p90RSK might contribute to the
dephosphorylation of eEF2, especially at earlier times where
its activation is maximal (Fig. 2A). To test this idea, we tested
the e¡ects of PD098059 and rapamycin on the ability of PE to
induce the dephosphorylation of eEF2 at an early time point,
where p90RSK activation is maximal and S6K1 activation has
not yet occurred (5 min). At this time, the decrease in eEF2
phosphorylation is of course smaller, but is signi¢cant and
reproducible. As shown in Fig. 3C, PD098059 blocked the
dephosphorylation of eEF2 at this time without a¡ecting its
levels in control cells. This indicates that MEK/Erk signalling
contributes to dephosphorylation of eEF2 even at an early
time prior to activation of S6K1: this could indicate that
activation of p90RSK is enough to induce the dephosphoryla-
tion of eEF2 and is studied further below. Surprisingly, rapa-
mycin also blocked the PE-induced dephosphorylation of
eEF2 at 5 min, a time when S6K1 (Fig. 2B) and S6K2 [18]
are not activated.
One possible explanation for this is that the e¡ect of rapa-
mycin on the phosphorylation of eEF2 also involves an input
from protein phosphatase activity. The major protein phos-
phatase acting on mammalian eEF2 is thought to be PP2A
[31,32]. PP2A can interact with the regulatory protein K4 [33],
which is related to the protein Tap42p, which is implicated in
the control of translation by TOR in yeast [34]. Indeed, there
is evidence that K4 modulates the phosphorylation of eEF2
via its interaction with PP2A [35]. It is clearly possible that the
e¡ect of rapamycin of eEF2 phosphorylation involves inputs
from PP2A/K4 as well as from the regulation of eEF2 kinase
by S6K. Further analysis of this lies beyond the scope of this
study.
3.4. Dephosphorylation of eEF2 in response to ET-1 or PE
does not involve signalling via PI 3-kinase
Earlier data showed that the dephosphorylation of eEF2
caused by insulin or angiotensin was blocked by inhibition
of PI 3-kinase [9,16]. To study whether PI 3-kinase is involved
in the e¡ects of PE and ET-1 on the phosphorylation of eEF2,
we treated ARVC with wortmannin prior to challenging them
with PE or ET-1. We previously showed that the doses of
wortmannin used here block PI 3-kinase signalling (it prevents
the activation of protein kinase B induced by insulin [17]).
Over a 100-fold range of concentrations, wortmannin had
no e¡ect on the ability of PE or ET-1 to elicit the dephos-
phorylation of eEF2 (Fig. 4A,B). Thus, PE and ET-1 regulate
eEF2 phosphorylation by mechanisms that do not require PI
3-kinase. This is consistent with a role of S6K1 in these e¡ects
as wortmannin does not block its activation by PE [17] and
ET-1 (data not shown).
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Fig. 2. Time courses of activation of p90RSK and S6K1 by PE in
ARVC. ARVC were treated with PE (10 WM) for the times indi-
cated and cells were then lysed and equal amounts of cell extract
protein were subjected to immunoprecipitation with anti-p90RSK (A)
or anti-S6K1 (B). Immunoprecipitates were assayed for kinase activ-
ity as described in the methods. Data are meanSS.D. (n=6; i.e.
data are from six experiments, each using a di¡erent batch of car-
diomyocytes).
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Fig. 3. Dephosphorylation of eEF2 in response to PE or ET-1 is
blocked by rapamycin or PD098059. ARVC were treated with PE
(10 WM; panels A,C), ET-1 (0.1 WM; panel B) or vehicle (MeOH)
for the indicated times in the presence or absence of PD098059 (50
WM, added 45 min before agonist) or rapamycin (100 nM, added 30
min before agonist). Samples were then analysed as described for
Fig. 1. These experiments were performed at least three times with
similar results.
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3.5. Activated MEK drives the dephosphorylation of eEF2 in an
mTOR-independent manner
The above data are consistent with a role for S6K1 (and
probably S6K2) in regulating the phosphorylation state of
eEF2 in response to PE or ET-1. It remained to be established
whether activation of p90RSK itself could su⁄ce to bring
about the dephosphorylation of eEF2, as one might expect
from in vitro experiments [11]. Analysis of its role in the
e¡ects of PE or ET-1 is complicated by the fact that, although
the time courses of activation of S6K1/2 and p90RSK di¡er,
they do overlap (Fig. 2; [17,18]). As an alternative approach
to studying this, we therefore explored the e¡ects of prolonged
activation of p90RSK on eEF2 phosphorylation. This was
achieved by expressing an activated form of MEK
(MEKCA) using an adenoviral vector [24]. As negative con-
trol, we used virus encoding LacZ. Infection of ARVC with
this virus had no e¡ect on the activity of p90RSK or the phos-
phorylation of S6K1 [17] or of eEF2 (Fig. 5). Expression of
MEKCA caused a marked increase in p90RSK activity which
was, as expected, reduced to basal levels by application of the
MEK inhibitor PD098059 (Fig. 5A). In contrast, rapamycin
had no e¡ect on the activity of p90RSK. MEKCA expression
also caused an increase in the phosphorylation of S6K1, as
manifested by a retardation of its mobility on SDS^PAGE
(Fig. 5B). Phosphorylation of S6K1 leads to its activation
[13] and these data are consistent with our earlier studies
showing that expression of MEKCA causes activation of
S6K1 (and S6K2) in ARVC [17,18], e¡ects which are blocked
by rapamycin and by PD098059. Expression of MEKCA led to
dephosphorylation of eEF2 and as expected this e¡ect was
blocked by the MEK inhibitor (Fig. 5C). However, the
MEKCA-induced dephosphorylation of eEF2 was not a¡ected
by rapamycin, indicating that activation of ERK signalling
can induce dephosphorylation of eEF2 without a requirement
for activation of S6K1. The simplest explanation for this,
consistent with the present data and those published earlier
[11,17], is that p90RSK can mediate the inactivation of eEF2
kinase in vivo, leading to dephosphorylation and activation of
eEF2.
3.6. Concluding remarks
The data presented here show that the Gq-coupled receptor
agonists PE and ET-1 each induce the dephosphorylation of
eEF2 in cardiac myocytes. These agents activate protein syn-
thesis and induce hypertrophy, and it is likely that the activa-
tion of eEF2 contributes to these end e¡ects. The present data
also show that signalling via MEK and mTOR is required for
the modulation of eEF2 phosphorylation under these condi-
tions. This is likely to involve phosphorylation and inactiva-
tion of eEF2 kinase by p90RSK/S6K1, which are downstream
components of these signalling pathways [11]. The e¡ect of
rapamycin may also involve inputs from PP2A to the regula-
tion of eEF2 phosphorylation [35]. The data showing that
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Fig. 4. Wortmannin does not block the dephosphorylation of eEF2
by PE or ET-1. ARVC were treated with PE (10 WM; 60 min; pan-
el A) or ET-1 (0.1 WM; 30 min; panel B) in the presence or absence
of wortmannin (WM; concentrations indicated; added 15 min be-
fore agonist and again 15 min after agonist as this compound is un-
stable in aqueous solution). Samples were then analysed as de-
scribed for Fig. 1. These experiments were performed at least three
times with similar results.
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Fig. 5. Expression of activated MEK induces dephosphorylation of eEF2 in ARVC. ARVC were left uninfected (‘control’), or infected with ad-
enovirus (multiplicity of infection (m.o.i.) 10) encoding lacZ (AxLacZ, as control for e¡ects of adenoviral infection) or activated MEK
(AxMEKCA, 10 m.o.i.). 36 h later, cells were treated (for 4 h) with PD098059 (50 WM) or rapamycin (rap; 100 nM). Cells were then lysed and
samples of extracts were used for analysis of p90RSK activity (A) or subjected to SDS^PAGE and Western blotting (B,C). B: The blot was de-
veloped with anti-S6K1 antiserum. The labelled arrows indicate the di¡erently migrating species of S6K1, which di¡er in their states of phos-
phorylation, so that the most highly phosphorylated (ppp; active) forms of S6K1 migrate slowest. C: Blots were developed with anti-eEF2
(Thr56[P]) or (as loading control) anti-eEF2 that recognises eEF2, whether or not it is phosphorylated. In A, data are derived from four sepa-
rate experiments; in B and C, experiments were performed four times with similar results.
FEBS 26686 23-10-02
L. Wang, C.G. Proud/FEBS Letters 531 (2002) 285^289288
MEK signalling is critical in regulating eEF2 phosphorylation
in adult rat cardiomyocytes is similar to the ¢nding that
blocking MEK inhibited the ability of a quite distinct G-pro-
tein coupled receptor agonist, angiotensin II, to induce de-
phosphorylation of eEF2 in neonatal cardiomyocytes [16].
However, this agonist works through additional pathways to
PE/ET-1 since, in addition to Gq, it activates Gi and signal-
ling via PI 3-kinase and the dephosphorylation of eEF2 in-
duced by angiotensin II required PI 3-kinase signalling [16], in
contrast to the data reported here. These data add to the
growing number of examples where MEK/Erk signalling reg-
ulates the phosphorylation or activity of components of the
translational machinery in mammalian cells [16,17,36^38].
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